API Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
Research and Markets has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015–2019" report to their offering.
The API market in the US to grow at a CAGR of 7% over the period 2014-2019.
A major trend upcoming in the API market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy.
According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents.
Further, the report states that stringent regulations are one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors.
Key Vendors
• Abbott Laboratories
• Aurobindo Pharma
• Mylan
• Teva Pharmaceutical Industries
Other Prominent Vendors
Albemarle
• Aptuit
• BASF
• Biocon
• Boehringer Ingelheim
• Cambrex
• Cipla
• Dr. Reddy's Laboratories
• Hospira
• Lonza Group
• Novartis
• Pfizer
• Sigma-Aldrich
• Sun Pharmaceutical Industries
Key Topics Covered:
1. Executive Summary
2. List of Abbreviations
3. Scope of the Report
4. Market Research Methodology
5. Introduction
6. Market Landscape
7. API Market in the US
8. Market Segmentation by Type of Production Process
9. Market Segmentation by Type of Product
10. Market Segmentation by Type of Players
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance